Mini-Review

Molecular Mechanisms of Arterial Stiffening

Marina Cecelja Phil Chowienczyk

King's College London British Heart Foundation Centre, Department of Clinical Pharmacology, St. Thomas' Hospital, London, UK

Key Words

Arterial calcification · Arterial stiffening · Cardiovascular disease · Genomic studies · Vascular aging

Abstract

Stiffening of large arteries is a hallmark of vascular aging and one of the most important determinants of the age-related increase in blood pressure and cardiovascular disease events. Despite a substantial genetic component, the molecular mechanisms underlying phenotypic variability in arterial stiffness remain unknown. Previous genetic studies have identified several genetic variants that are associated with measures of arterial stiffness. Here, we review the relevant advances in the identification of pathways underlying arterial stiffness from genomic studies.

© 2016 S. Karger AG, Basel

Arterial Stiffness as a Risk Factor and Target for Treatment

Stiffening of the aorta and large elastic arteries is a hallmark of vascular aging [1]. It has a number of adverse haemodynamic consequences, including a major contribution to isolated systolic hypertension [2–4]. When measured by aortic pulse wave velocity (aPWV), it is highly predictive of clinical cardiovascular disease events independent of blood pressure, both in the general population and in groups with additional risk factors [5, 6]. Formerly thought to be simply a marker of atherosclerosis [7], the pathology of aortic stiffening may differ, at least in part, from that of atherosclerosis [8–10]. Thus, in primate models of atherosclerosis, aPWV is reduced compared to non-atherosclerotic controls, at least in the early stages of atheroscle-

Dr. Marina Cecelja
Department of Clinical Pharmacology, St. Thomas' Hospital
Lambeth Palace Road
London SE1 7EH (UK)
E-Mail marina.3.cecelja@kcl.ac.uk

rosis [10]. In humans, aPWV is largely independent of risk factors other than age and blood pressure [11] and is not elevated in the presence of non-calcified atheromatous plaque [8, 9]. The prognostic importance of arterial stiffening and the fact that it may be driven by a specific pathology distinct from atherosclerosis makes it an appealing target to prevent cardiovascular disease events.

Arterial Calcification as a Cause of Arterial Stiffening

In older subjects, calcification occurs in the media of the arterial wall around elastin fibres ('elastocalcinosis') [12] and within atherosclerotic plaque in the intima [13]. Although often regarded as distinct entities, intimal and medial calcifications often coexist. Arterial stiffening is closely associated with calcification, an association that could be explained by coexistent atherosclerosis [7]. However, animal models show that medial calcification (in the absence of atherosclerosis) increases arterial stiffness, suggesting a direct causal relation between calcification and stiffening [14]. Using combined computed tomography and magnetic resonance imaging to measure calcification and atheroma in the Twins UK population, we have shown that even though calcification often colocalises with atherosclerotic plaque, the association of stiffness with calcification is not explained by coexistent atheromatous plaque [8]. Furthermore, the correlation between calcification and stiffness is explained by shared genetic factors distinct from those responsible for atherosclerosis [8, 9].

Arterial calcification is now known to be an active process resembling osteogenesis in which vascular smooth muscle cells undergo osteoblastic differentiation, expressing many of the proteins associated with bone formation [13] and releasing vesicles into the extracellular matrix which serve as nucleation sites for the accumulation of hydroxyapatite crystals [15, 16]. In culture media, high concentrations of calcium and phosphate induce osteoblastic differentiation of vascular smooth muscle cells [16, 17]. Pre-dialysis- and dialysis-dependent patients with chronic kidney diseases have high circulating calcium phosphate products and develop extensive calcification and arterial stiffening [18]. Precipitation of calcium in tissue in healthy subjects is inhibited by numerous regulatory factors including matrix gla protein, fetuin, klotho and fibroblast growth factor 23 [13]. It is likely that initiation and progression of calcification is dependent on the complex interactions between promoters and inhibitors of calcification.

Contribution of Changes in the Extracellular Matrix

Whilst calcification may represent the later stages of a degenerative arteriosclerotic process that can be detected macroscopically, it is likely to be initiated by elastin degradation and a change in the type of collagen, which may also contribute to arterial stiffening independent of calcification [14]. Such a degenerative process may relate to repetitive mechanical stress (heart rate $\times$ blood pressure product) [19]. It is thought to promote calcification through elastin-derived soluble peptides (matrikines or elastokines) which activate smooth muscle cell osteogenic differentiation [20] and increase matrix affinity for nucleating mineral deposition [21]. Matrix metalloproteinases (MMPs) degrade components of the extracellular matrix including elastin, and in vivo, MMP-mediated elastin degradation is closely associated with both medial calcification and increased arterial stiffness [22, 23]. MMPs are also implicated in cutaneous elastin degradation that may parallel changes in the arterial wall [24, 25].

Genetics of Arterial Stiffness

Heritability of arterial stiffness is approximately 40% as estimated from twin and family studies [26–28]. Candidate gene approaches have identified single-nucleotide polymorphisms related to arterial stiffness on genes potentially implicated in the regulation of the extracellular matrix and calcification: MMPs [29, 30], collagen 1 [31], fibrillin 1 [32] and ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (*ENPP1*, an inhibitor of calcification) [33] in addition to genes relating to blood pressure regulation [34–36], and inflammation [37, 38]. Genome-wide association studies (GWAS) have only identified a small number of genetic variants reaching genome-wide significance. The collagen type IV alpha 1 (*COL4A1*) gene polymorphism on chromosome 13 (collagen type 4) was significantly associated with higher arterial stiffness [39] in one study, but the association failed to be replicated in a recent GWAS meta-analysis of 11 community-based cohorts. A significant association in the 3'-B-cell lymphoma/leukaemia 11B (3'-BCL11B) gene desert located on chromosome 14 did achieve genome-wide significance, but its potential role in arterial stiffening remains to be established [40].

The limitations of GWAS in identifying causal genes in hypertension, arterial stiffness and other common conditions are increasingly recognised and include limited power to identify common variants with a modest effect size, lack of coverage of rare variants, genetic interactions and gene $\times$ environment interactions [41, 42]. In addition, identified single-nucleotide polymorphisms are often located in intergenic or non-coding regions, and it is not clear which gene is the causal gene or the regulatory pathway/network. Thus, it is of interest to examine whether gene expression, an intermediate step between genetic variation and structural and functional variation, may be related more closely to the phenotype.

Blood-based gene expression tests have previously been associated with a wide range of non-haematological disorders including coronary artery disease [43–46] and hypertension [47]. While the exact nature of these associations remains unknown, they may either reflect parallel changes in gene expression across tissues or participation of haematological factors in the disease process. Where similar pathways may operate in parallel in vascular and non-vascular tissues, there may be a direct correlation of gene expression in sample tissues with arterial tissue. MMP9 expression in the skin, for example, has been shown to relate to arterial stiffness [24]. Alternatively, there may be a direct correlation between gene expression in circulating leukocytes that participate in the pathogenesis of arteriosclerosis. In agreement with this, previous microarray data from Huang et al. [48] have identified the differential expression of several genes in circulating cells, including calcium- and bone-related genes, in individuals with and without vascular calcification.

Using the Twins UK cohort, we have investigated the association of gene expression levels with cross-sectional and longitudinal changes in arterial stiffening [49]. Genes were selected if they had previously been associated with arterial stiffening in genome-wide or candidate gene studies. We found that expression levels of *ENPP1*, a transmembrane glycoprotein enzyme that generates inorganic pyrophosphate and is associated with vascular calcification, were independently associated with PWV in a cross-sectional analysis. These findings were successfully replicated in a longitudinal analysis where *ENPP1* was a significant predictor of aPWV progression. We additionally found expression levels of *COL4A1*, which encodes for one component of type IV collagen, to be significantly associated with progression of PWV. Possible biological pathways and gene networks linking *ENPP1* and *COL4A1* to arterial stiffness and calcification were identified using the Ingenuity Knowledge Base (fig. 1) [49].

Fig. 1. Conceptual pathway linking *COL4A1* and *ENPP1* with arterial stiffness using the Ingenuity Pathway Analysis knowledge database. Activation of the calcium-sensing receptor (CASR) acts on the transcriptional regulator catenin (cadherin-associated protein) beta 1 (CTNNB1) which initiates the transcription of *ENPP1* and *COL4A1*. Increased *ENPP1* expression may lead to arterial stiffening through its effect on calcification, or it may trigger osteopontin (SPP1) and influence the extracellular matrix through its effects on MMP2/9 [49].

Conclusion

Despite the prognostic importance of arterial stiffness, very little is known regarding the molecular mechanisms of stiffening. Unique approaches utilising both genetic variants and gene expression data and their associations with particular phenotypes may help to identify novel pathways, likely involving calcification/extracellular matrix degradation, for interventions to prevent or reverse arterial stiffening. In particular, combining this with longitudinal studies may elucidate different mechanisms determining arterial stiffness at different vascular ages that are specific to the human aorta. Due to the unique characteristics of the human aorta with the predominance of extracellular matrix and coexistent atheromatous disease, animal models may be of limited use in identifying such mechanisms but could be important for validating the findings of genetic studies to test the role of genes in pathways influencing both muscular and elastic arteries.

Disclosure Statement

The authors declare that they have no conflicts of interest.

References

- 1 Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF: Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. *Circulation* 1983;68:50–58.
- 2 Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, et al: Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. *Hypertension* 2007;50:228–233.
- 3 Cecelja M, Chowienzyk P: Role of arterial stiffness in cardiovascular disease. *JRSM Cardiovasc Dis* 2012;1.
- 4 Cecelja M, Jiang B, Spector TD, Chowienzyk P: Progression of central pulse pressure over 1 decade of aging and its reversal by nitroglycerin: a twin study. *J Am Coll Cardiol* 2012;59:475–483.
- 5 Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation* 2006;113:664–670.
- 6 Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al: Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J* 2006;27:2588–2605.
- 7 van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, et al: Association between arterial stiffness and atherosclerosis: the Rotterdam study. *Stroke* 2001;32:454–460.
- 8 Cecelja M, Hussain T, Greil G, Botnar R, Preston R, Moayyeri A, et al: Multimodality imaging of subclinical aortic atherosclerosis: relation of aortic stiffness to calcification and plaque in female twins. *Hypertension* 2013;61:609–614.
- 9 Cecelja M, Jiang B, Bevan L, Frost ML, Spector TD, Chowienzyk PJ: Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. *J Am Coll Cardiol* 2011;57:1480–1486.
- 10 Farrar DJ, Bond MG, Riley WA, Sawyer JK: Anatomic correlates of aortic pulse wave velocity and carotid artery elasticity during atherosclerosis progression and regression in monkeys. *Circulation* 1991;83:1754–1763.
- 11 Cecelja M, Chowienzyk P: Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. *Hypertension* 2009;54:1328–1336.
- 12 Demer LL, Tintut Y: Vascular calcification: pathobiology of a multifaceted disease. *Circulation* 2008;117:2938–2948.
- 13 Demer LL: Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. *Int J Epidemiol* 2002;31:737–741.
- 14 Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J: Calcification of medial elastic fibers and aortic elasticity. *Hypertension* 1997;29:999–1006.
- 15 Kim KM: Calcification of matrix vesicles in human aortic valve and aortic media. *Fed Proc* 1976;35:156–162.
- 16 Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. *J Am Soc Nephrol* 2004;15:2857–2867.
- 17 Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM: Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. *Biochem Biophys Res Commun* 2000;277:736–740.
- 18 Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. *Arterioscler Thromb Vasc Biol* 1998;18:535–541.
- 19 McEniery CM, Spratt M, Munnelly M, Yarnell J, Lowe GD, Rumley A, et al: An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. *Hypertension* 2010;56:36–43.
- 20 Duca L, Floquet N, Alix AJ, Haye B, Debelle L: Elastin as a matrikine. *Crit Rev Oncol Hematol* 2004;49:235–244.
- 21 Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR: Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. *Circulation* 2004;110:3480–3487.
- 22 Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, Wallace S, et al: Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. *Arterioscler Thromb Vasc Biol* 2006;26:1799–1805.
- 23 Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al: Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. *Arterioscler Thromb Vasc Biol* 2005;25:372.
- 24 MacLay JD, McAllister DA, Rabinovich R, Haq I, Maxwell S, Hartland S, et al: Systemic elastin degradation in chronic obstructive pulmonary disease. *Thorax* 2012;67:606–612.
- 25 Steed MM, Tyagi SC: Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. *Antioxid Redox Signal* 2011;15:1927–1943.
- 26 Mitchell GF, DeStefano AL, Larson MG, Benjamin EJ, Chen MH, Vasan RS, et al: Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. *Circulation* 2005;112:194–199.
- 27 North KE, MacCluer JW, Devereux RB, Howard BV, Welty TK, Best LG, et al: Heritability of carotid artery structure and function: the Strong Heart Family Study. *Arterioscler Thromb Vasc Biol* 2002;22:1698–1703.
- 28 Sayed-Tabatabaei FA, van Rijn MJ, Schut AF, Aulchenko YS, Croes EA, Zillikens MC, et al: Heritability of the function and structure of the arterial wall: findings of the Erasmus Rucphen Family (ERF) study. *Stroke* 2005;36:2351–2356.

- 29 Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA: Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. *Arterioscler Thromb Vasc Biol* 2004; 24:1479–1484.
- 30 Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ: Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. *Circ Res* 2003;92:1254–1261.
- 31 Brull DJ, Murray LJ, Boreham CA, Ralston SH, Montgomery HE, Gallagher AM, et al: Effect of a COL1A1 Sp1 binding site polymorphism on arterial pulse wave velocity: an index of compliance. *Hypertension* 2001;38: 444–448.
- 32 Medley TL, Cole TJ, Gatzka CD, Wang WY, Dart AM, Kingwell BA: Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. *Circulation* 2002;105:810–815.
- 33 Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A, et al: Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. *Nephrol Dial Transplant* 2008;23:321–327.
- 34 Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, et al: Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. *Circulation* 1996;94:698–703.
- 35 Chen W, Srinivasan SR, Boerwinkle E, Berenson GS: Beta-adrenergic receptor genes are associated with arterial stiffness in black and white adults: the Bogalusa Heart Study. *Am J Hypertens* 2007;20:1251–1257.
- 36 Czarnecka D, Kawecka-Jaszcz K, Stolarz K, Olszanecka A, Dembinska-Kiec A, Kiec-Wilk B: Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study. *J Hum Hypertens* 2005;19: 413–420.
- 37 Morita A, Nakayama T, Doba N, Hinohara S, Soma M: Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP level and arterial pulse wave velocity in healthy elderly Japanese. *Hypertens Res* 2006; 29:323–331.
- 38 Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, et al: Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. *Hypertension* 2008;51:1651–1657.
- 39 Tarasov KV, Sanna S, Scuteri A, Strait JB, Orru M, Parsa A, et al: COL4A1 is associated with arterial stiffness by genome-wide association scan. *Circ Cardiovasc Genet* 2009;2:151–158.
- 40 Mitchell GF, Verwoert GC, Tarasov KV, Isaacs A, Smith AV, Yasmin, et al: Common genetic variation in the 3'-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium. *Circ Cardiovasc Genet* 2012;5:81–90.
- 41 Steves CJ, Spector TD, Jackson SH: Ageing, genes, environment and epigenetics: what twin studies tell us now, and in the future. *Age Ageing* 2012;41:581–586.
- 42 Zhang W, Li F, Nie L: Integrating multiple 'omics' analysis for microbial biology: application and methodologies. *Microbiology* 2010;156:287–301.
- 43 Elashoff MR, Nuttall R, Beineke P, Doctolero MH, Dickson M, Johnson AM, et al: Identification of factors contributing to variability in a blood-based gene expression test. *PLoS One* 2012;7:e40068.
- 44 Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, et al: Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. *BMC Med Genomics* 2011;4:26.
- 45 Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, et al: Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. *Ann Intern Med* 2010;153:425–434.
- 46 Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, et al: Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. *J Cardiovasc Transl Res* 2012;5:366–374.
- 47 Huan T, Esko T, Peters MJ, Pilling LC, Schramm K, Schurmann C, et al: A meta-analysis of gene expression signatures of blood pressure and hypertension. *PLoS Genet* 2015;11:e1005035.
- 48 Huang CC, Lloyd-Jones DM, Guo X, Rajamannan NM, Lin S, Du P, et al: Gene expression variation between African Americans and whites is associated with coronary artery calcification: the multiethnic study of atherosclerosis. *Physiol Genomics* 2011;43:836–843.
- 49 Cecelja M, Jiang B, Mangino M, Spector TD, Chowienzyk PJ: Association of cross-sectional and longitudinal change in arterial stiffness with gene expression in the Twins UK cohort. *Hypertension* 2016;67:70–76.